Back to top
more

ThermoGenesis (THMO)

(Delayed Data from OTC)

$0.15 USD

0.15
21,829

+0.02 (16.23%)

Updated Jul 12, 2024 03:15 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 30.61% and 46.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 3.92% and 45.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 20% and 70.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 2.86% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 26.32% and 5.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -1,000% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Solid Biosciences Inc. (SLDB) Reports Q4 Loss, Lags Revenue Estimates

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15% and 9.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for August 31st

AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.

ThermoGenesis Holdings, Inc. (THMO) Reports Q2 Loss, Tops Revenue Estimates

ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -111.11% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ThermoGenesis Holdings, Inc. (THMO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

ThermoGenesis Holdings, Inc. (THMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for July 2nd

PDCO, SABR, JRSH, UPWK, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2021

New Strong Sell Stocks for December 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

New Strong Sell Stocks for November 18th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Stock Market News for Aug 25, 2020

The S&P 500 and the Nasdaq hit an all-time high on Monday after news of a potential coronavirus treatment lifted investors' sentiment.

Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex

Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Disappointing Data

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

ThermoGenesis Holdings, Inc. (THMO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in ThermoGenesis Holdings, Inc. (THMO).